Search
Enflurane
go.drugbank.com/drugs/DB00228ApprovedVet approvedWithdrawnEnflurane is a halogenated inhalational anesthetic initially approved by the FDA in 1972. Since this date, it has been withdrawn from the US market.
Elasomeran
go.drugbank.com/drugs/DB15654ApprovedInvestigational[L39160, L39277] A similar booster dose is also available in the US for patients 18 years of age and older. … For the 2024-2025 season, an updated formulation was approved for use in Canada and the US to target the Omicron KP.2 subvariant.[L51404,L40074]
Tiopronin
go.drugbank.com/drugs/DB06823ApprovedIt is similar to d-penicillamine in use and efficacy, but offers the advantage of far less adverse effects.
Capecitabine
go.drugbank.com/drugs/DB01101ApprovedInvestigationalCapecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, wh...
Baricitinib
go.drugbank.com/drugs/DB11817ApprovedInvestigational[L41760] Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults [A248395] and was later approved by the FDA in 2018. … By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses.
Alanine
go.drugbank.com/drugs/DB00160ApprovedInvestigationalNutraceuticalIt is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and the central nervous system.
Mixtures: PF K-CAMINE %8 AMINO ASIT IV INFUZYON ICIN COZELTI, 1000 ML (SETLI), PF K-CAMINE %8 AMINO ASIT IV INFUZYON ICIN COZELTI, 500 ML (SETLI)Voretigene neparvovec
go.drugbank.com/drugs/DB13932ApprovedInvestigational[A31478] VN-rzyl was developed by Spark Therapeutics Inc. and FDA approved on December 19, 2017.[L1095] … When used in genetic therapy, this virus is modified for the elimination of its negligible integrative capacity by the removal of *rep* and *cap* and the insertion of the desired gene with its promoter
Propoxycaine
go.drugbank.com/drugs/DB09342ApprovedUsed in combination with procaine, it was the only dental local anesthetic available in cartridge form [L1592]. … This drug was removed from the US market in 1996.
Esmolol
go.drugbank.com/drugs/DB00187ApprovedInvestigationalWithdrawnThe FDA withdrew its approval for the use of all parenteral dosage form drug products containing esmolol hydrochloride that supply 250 milligrams/milliliter of concentrated esmolol per 10-milliliter ampule … It has a rapid onset but short duration of action without causing significant intrinsic sympathomimetic or membrane stabilizing activities at recommended therapeutic doses.
Tozinameran
go.drugbank.com/drugs/DB15696ApprovedInvestigational[A225386] Comirnaty was granted a EUA in the UK on December 2, 2020,[L26676] and in Canada on December 9, 2020[L26671] for active immunization against SARS-CoV-2. … [L15017, L15022] Comirnaty received fast track designation by the U.S. FDA on July 13, 2020.